Abbott Laboratories trades at $105.70 after a 16% decline this year, with Barclays forecasting significant gains ahead.
Barclays analyst Matt Miksic raised Abbott Laboratories’ (NYSE:ABT) price target to $143, implying 35% upside from its current $105.70 level. The firm cited five consecutive adjusted EPS beats, despite costs tied to the $21 billion Exact Sciences acquisition closing March 23, 2026.
Abbott’s forward P/E stands at 19x, with 54 straight years of dividend hikes. The S&P 500 has gained 9.55% year-to-date, while ABT declined 16%. Management lifted full-year adjusted EPS guidance to a range of $5.45 to $5.60, signaling confidence in H2 2026 growth.
The Street’s consensus target for ABT is $118.42, reflecting 12% upside. Abbott’s $182.9 billion market cap spans medical devices, diagnostics, and nutrition, with key franchises like FreeStyle Libre driving stability.